Salipro Biotech Secures Key US Patent, Fortifying Drug Discovery Frontier

STOCKHOLM, Sweden – February 17, 2026 – Salipro Biotech AB, a pioneering Swedish company, has significantly strengthened its position in the global biopharmaceutical landscape with the grant of U.S. Patent No. 12,383,501. The patent, titled “Production of Salipro Particles,” provides robust intellectual property protection for the company's core Salipro® platform technology in the major U.S. market until June 2042.

This development solidifies the company’s role as a leader in stabilizing challenging membrane proteins, a critical step in discovering new drugs against previously inaccessible targets. The patent protects a key method for directly extracting and purifying these delicate proteins, a capability essential for advancing research on targets like G protein-coupled receptors (GPCRs), ion channels, and SLC transporters.

“This new U.S. patent represents an important milestone in the continued expansion of our global IP portfolio,” said Jens Frauenfeld, CEO of Salipro Biotech, in a statement. “Our Salipro® platform is already powering partnered drug discovery programs worldwide, and this patent further enhances the defensibility and value of our platform for our strategic partners.”

Cracking the Code of 'Undruggable' Proteins

Membrane proteins are the gatekeepers and communicators of the cell, playing a fundamental role in nearly every biological process. They are the targets for over 60% of all currently approved medicines, making them immensely valuable in pharmacology. However, their nature makes them notoriously difficult to study. Embedded within the cell’s lipid membrane, they are inherently unstable when removed, often unfolding and losing their function when extracted with traditional detergent-based methods. This instability has created a class of so-called “undruggable” targets, hindering the development of therapies for numerous diseases.

Salipro Biotech’s platform offers an elegant solution to this long-standing problem. The company's proprietary DirectMX™ technology bypasses the need for harsh detergents. Instead, it uses a scaffold protein to directly envelop and extract membrane proteins from the cell while retaining their native lipid environment. The result is a stable, soluble nanoparticle—a Salipro® particle—that holds the membrane protein in its active, functional state.

This breakthrough allows scientists to treat these complex proteins as if they were simple, soluble proteins. It unlocks a full suite of modern drug discovery techniques that were previously unfeasible, including high-resolution structural analysis via cryo-electron microscopy (cryo-EM), biophysical characterization with surface plasmon resonance (SPR), and high-throughput screening of small molecules and biologics. By providing a steady supply of high-quality, functional targets, the technology significantly accelerates the initial, most challenging phases of drug development.

A Strategic Power Play in the Biotech Arena

The grant of this foundational U.S. patent is more than a scientific validation; it is a critical business move that reshapes the competitive landscape. With protection extending to 2042, Salipro Biotech has secured a long-term competitive advantage for its core production method. This legal fortress around its technology enhances its value proposition in a market where other membrane-mimetic systems, such as nanodiscs and amphipols, also compete for dominance.

This robust IP portfolio, which now includes over 60 granted patents worldwide, makes the company an exceptionally attractive collaborator for pharmaceutical giants. Major players are increasingly looking to outsource complex R&D and partner with specialized biotechs to fill their drug pipelines. Salipro Biotech has already established a strong track record of such collaborations, with active programs involving industry leaders like AstraZeneca and Boehringer Ingelheim. For instance, a collaboration with AstraZeneca utilized the Salipro® platform to enable structural studies of the PANX1 ion channel, while Boehringer Ingelheim recently exercised a licensing option for a target developed using the technology.

For investors and potential partners, the new patent de-risks investment by guaranteeing market exclusivity for a prolonged period. This legal security, combined with proven scientific success, elevates the company's valuation and strengthens its negotiating position in future licensing deals, funding rounds, or potential strategic acquisitions.

Fueling a Multi-Billion Dollar Drug Discovery Market

Salipro Biotech's advance is perfectly timed with a period of explosive growth and technological evolution in the drug discovery sector. The global market, valued at nearly $72 billion in 2025, is on a trajectory to more than double to approximately $159 billion by 2034. A significant portion of this growth is driven by the very targets Salipro's technology makes accessible.

The market for purified membrane proteins alone is projected to grow from $1.8 billion in 2024 to over $3.2 billion by 2030, with GPCRs and ion channels accounting for almost half of that expansion. The global GPCR market is forecast to reach $3.7 billion by 2026, while the market for ion channel modulators is expected to hit $17.2 billion by 2035, fueled in part by a surge in the use of Artificial Intelligence (AI) for screening complex targets.

Salipro’s platform is uniquely positioned to capitalize on these converging trends. Its ability to produce stable, high-quality proteins is a critical enabler for AI-driven drug design and structure-based methods like cryo-EM, which are becoming the industry standard. As the pharmaceutical world shifts towards precision medicine and therapies tailored to specific protein subtypes, the need for a technology that can reliably deliver these targets has never been greater.

Paving the Way for Future Therapies

Ultimately, the significance of this patent extends beyond corporate strategy and market dynamics to the potential for profound human impact. By unlocking the door to previously intractable drug targets, the Salipro® platform opens new avenues for developing treatments for some of the world's most challenging diseases.

GPCRs, ion channels, and SLC transporters are deeply implicated in a wide range of conditions, including neurological disorders, cardiovascular disease, metabolic syndromes, and many forms of cancer. The ability to effectively target these proteins could lead to the creation of novel, more effective therapeutics where options are currently limited or non-existent.

By overcoming a fundamental bottleneck in research and development, this technological advancement promises to shorten the timeline from laboratory discovery to clinical application. This fusion of scientific innovation and robust legal protection positions the Salipro® platform as a pivotal engine for the future of therapeutic development.